Compare Mesoblast Limited (MESO) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Mesoblast Limited trades at $16.74 (market cap $2.21B), while Direxion Daily S&P 500 Bull 3X Shares trades at $295.35. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | SPXL | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $20.96 | $296.39 |
52-Week Low | $12.88 | $170.20 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
SPXL trades at $295.39, down 0.27% in the last session, with technical indicators showing a bullish trend from moving averages but overbought signals from RSI levels above 70. The stock's pivot point at $294 and resistance at $296 suggest near-term price sensitivity. Recent news highlights S&P 500 record highs and AI-driven earnings optimism, though valuation concerns persist.
Outlook remains cautiously optimistic amid strong market momentum, with opportunities from AI growth and corporate earnings, but risks include high valuations and potential pullbacks. Investors should balance bullish technicals with fundamental prudence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
